Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a ...

Anne Wojcicki's nonprofit TTAM acquires 23andMe for $305 million, ending the gene-testing pioneer's bankruptcy saga. The deal still faces state regulators' objections over genetic data control.

Anne Wojcicki, co-founder of 23andMe, a DNA testing company, has won back control of the firm through a bankruptcy court sale.

Regeneron Pharmaceuticals will acquire embattled DNA testing company 23andMe in a $256 million court-supervised sale, promising to honor existing privacy protections and continue consumer services ...

Officials for retailer Claire's filed for bankruptcy protection on Wednesday as its operating costs rise while demand for its ...

Following the sale of the direct-to-consumer genetic testing company 23andMe, the Utah Attorney General’s Office is issuing a consumer advisory reminding former customers of ways to protect ...

In May, Regeneron Pharmaceuticals announced it would purchase most of 23andMe's assets for $256 million after it came out on top during the bankruptcy auction.

The sale, which was approved by U.S. Bankruptcy Judge Brian C. Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had ...

More than two dozen At Home stores are set to close by the end of September as the company continues to deal with dwindling sales and crippling debt.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the most profitable biotech stocks to invest in now. Canaccord updated estimates on Regeneron Pharmaceuticals, Inc.